<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163396</url>
  </required_header>
  <id_info>
    <org_study_id>ASL606LIOM01</org_study_id>
    <nct_id>NCT01163396</nct_id>
  </id_info>
  <brief_title>First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer</brief_title>
  <acronym>FOIB</acronym>
  <official_title>Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicentre phase II study evaluating the safety and
      efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line
      treatment of metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>PFS rate at 10 months from study entry</time_frame>
    <description>PFS was calculated from the day of treatment start to the first observation of disease progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>2007-2010</time_frame>
    <description>Response evaluation was performed every 8 weeks from the day of treatment start until disease progression for each enrolled patient for the full lenght of the study. Response evaluation was performed according to RECIST criteria. Responses were subsequently confirmed by a central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2007-2010</time_frame>
    <description>OS was calculated from the day of treatment start until death from any cause for each enrolled patient for the full lenght of the study, censoring patients who had not died at the last date known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2007-2010</time_frame>
    <description>During the full lenght of first-line treatment, number of enrolled patients reporting adverse events was recorded. Adverse events were evaluated according to National Cancer Institute Common Toxicity Criteria (version 3.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of potential surrogate markers predictive of bevacizumab activity</measure>
    <time_frame>2007-2010</time_frame>
    <description>During first-line therapy and at disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil/leucovorin</intervention_name>
    <arm_group_label>FOLFOXIRI plus bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed colorectal adenocarcinoma

          -  Unresectable and measurable metastatic disease (RECIST criteria)

          -  Male or female, aged &gt; 18 years and ≤ 75 years

          -  ECOG Performance Status (PS) &lt; 2 if aged &lt; 71 years

          -  ECOG PS = 0 if aged 71-75 years

          -  Life expectancy of more than 3 months

          -  Adequate haematological function: ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, Hb ≥ 9
             g/dL

          -  INR ≤ 1.5 and aPTT ≤ 1.5 x ULN within 7 days prior to starting study treatment

          -  Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and
             transaminases ≤ 2.5 x ULN (in case of liver metastases &lt; 5 x ULN)

          -  Serum Creatinine ≤ 1.5 x ULN

          -  Urine dipstick for proteinuria &lt; 2+. If urine dipstick is ≥ 2+, 24- hour urine must
             demonstrate ≤ 1 g of protein in 24 hours

          -  Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between
             the end of adjuvant therapy and first relapse

          -  At least 6 weeks from prior radiotherapy and 4 weeks from surgery

        Exclusion Criteria:

          -  Prior palliative chemotherapy

          -  Prior treatment with bevacizumab

          -  Bowel obstruction (or subobstruction)

          -  History of inflammatory enteropathy or extensive intestinal resection (&gt; hemicolectomy
             or extensive small intestine resection with chronic diarrhea)

          -  Symptomatic peripheral neuropathy &gt; 2 grade NCIC-CTG criteria

          -  Presence or history of CNS metastasis

          -  Active uncontrolled infections

          -  Active disseminated intravascular coagulation

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to treatment, or anticipation of the need for major surgery during the course of
             the study

          -  Central Venous Access Device (CVAD) for chemotherapy administration inserted within 2
             days prior to study treatment start

          -  Past or current history of malignancies other than colorectal carcinoma, except for
             curatively treated basal and squamous cell carcinoma of the skin cancer or in situ
             carcinoma of the cervix

          -  Clinically significant cardiovascular disease, for example cerebrovascular accidents
             (CVA) (≤ 6 months before treatment start), myocardial infarction (≤ 6 months before
             treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF),
             uncontrolled arrhythmia

          -  Uncontrolled hypertension

          -  24-hour urine protein &gt; 1 g if dipstick &gt; 2+

          -  History of thromboembolic or hemorrhagic events within 6 months prior to treatment

          -  Evidence of bleeding diathesis or coagulopathy

          -  Serious, non healing wound/ulcer or serious bone fracture

          -  No therapeutic anticoagulation or antiplatelet agents or NSAID with anti-platelet
             activity (aspirin ≤ 325 mg/day allowed)

          -  Pregnancy or lactation

          -  Fertile women (&lt; 2 years after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Falcone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

